Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, ...

Looking for a natural alternative to GLP-1 drugs? Integrative medicine physician Dr. Taz Bhatia has shared three foods that ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.